|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/04 | (2006.01) |
| A61K 31/535 | (2006.01) | ||
| A61P 35/00 | (2006.01) |
| (11) | Number of the document | 3040333 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16151719.8 |
| Date of filing the European patent application | 2011-09-29 | |
| (97) | Date of publication of the European application | 2016-07-06 |
| (45) | Date of publication and mention of the grant of the patent | 2018-09-12 |
| (46) | Date of publication of the claims translation | 2018-12-10 |
| (30) | Number | Date | Country code |
| 388721 P | 2010-10-01 | US | |
| 201161494915 P | 2011-06-09 | US |
| (72) |
CALIENNI, John Vincent, US
DE LA CRUZ, Marilyn, US
FLUBACHER, Dietmar, CH
GONG, Baoqing, US
KAPA, Prasad Koteswara, US
KARPINSKI, Piotr H., US
LIU, Hui, US
MICHEL, Pascal, CH
MOSE, Rasmus, CH
TESTA, Maria Caterina, CH
WAYKOLE, Liladhar Murlidhar, US
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | Kristalinės formos 5-(2,6-Di-4-morfolinil-4-pirimidinil)-4-trifluormetilpiridin-2-amino, PI3K inhibitoriaus |
| CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR |
| Payment date | Validity (years) | Amount | |
| 2024-09-16 | 14 | 289.00 EUR |
| 2025-09-29 |